Milestone
3.1.a
Preferred Product Characteristics
Not started
High priority
Building on existing TPPs, develop a broadly agreed upon and internationally vetted (e.g. through a process involving an international multilateral organization such as the WHO) set of PPCs to identify key product characteristics, including optimal and critical minimal criteria. These could follow a tiered approach, with an initial focus on variant-proof SARS-CoV-2 vaccines, then moving to other, more broadly protective tiers.